Odds ratios of exacerbation of chronic obstructive pulmonary disease with a 5°C decrease in mean temperature^# stratified by age, sex, vaccination and inhaled medicine. by Ching-Min Tseng (390343)

Inhibition of IL-17A at tumor sites decreases the intratumoral microvessel density. by Keiji Hayata (277090)

“…Data are representative of two independent experiments. Data are presented as means ± SE (<i>n</i> = 5). …”

UGGT activity decreases in <i>uggt-1(RNAi)</i> worms but no decrease was observed in <i>uggt-2 (RNAi)</i> worms. by Lucila I. Buzzi (198284)

Drugs which cluster on the 'anxiolytic' group decrease 5-HT turnover in the brain. by Caio Maximino (100467)

“…Points represent means and error bars represent standard errors. A negative correlation is found between the decrease in serotonin turnover and the increase in time on white produced by a drug (r² = 0.5688, p = 0.0073).…”

How Do Zn²⁺ Ions Promote Methane Activation on Zinc-Modified Zeolites? A Hybrid Quantum-Chemical Study by Zoya N. Lashchinskaya (8102741)

Subjects:

Quercetin decreases proliferation (A) and induces apoptosis (B) in cultured PASMC from control rats. by Daniel Morales-Cano (668199)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects: